Research and expertise
in the framework
of allergic and
environnemental diseases

ALYATEC is pleased and proud to announce the publication of positive results obtained in a clinical study conducted for the American company Regeneron Pharmaceuticals.

This phase 2 study completed in May 2020 aimed to evaluate the efficacy of a drug candidate for asthmatic patients allergic to cat.

These major results were presented for the first time at the 2021 AAAAI congress.